Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit

摘要

ABSTRACT We will provide the Alzheimer’s disease (AD) community with a novel assay resource based on advanced methodology that enables precise, highly specific, standardizable, multiplex quantification of the innate immunity- complement protein network in AD brain tissues. The innate immune response and its ties to inflammation are important to the pathophysiology of AD and represents a viable therapeutic target. Regulation of the immune system is the result of interplay amongst many 100s of proteins, and conventional protein quantification approaches (e.g. immunoassays) typically target one analyte at a time, which is not adequate for studying the behavior of a complex and robust signaling network such as innate immunity. We will develop multiplex assays to quantify proteins in the innate immune network, using a NextGen protein quantification platform based on a targeted form of mass spectrometry called multiple reaction monitoring (MRM). All assay protocols and validation data will be made publicly available as a novel resource to the community via the established, open-source NCI Assay Portal (assays.cancer.gov). We believe that this work is likely to stimulate additional work leading to progress on AD by providing the AD community with a novel assay resource based on advanced methodology that enables precise, highly specific, standardizable, multiplex quantification of the inflammation / innate immunity protein network in AD brains.